News & Updates
Filter by Specialty:
Long-term steroid OK for RA but challenges guidelines
Contrary to what current guidelines advocate, long-term use of corticosteroid works fine in older patients with rheumatoid arthritis (RA), suggests the much-anticipated GLORIA* trial presented at EULAR 2022.
Long-term steroid OK for RA but challenges guidelines
08 Jun 2022Weight loss intervention may improve COPD symptoms
In addition to cardiometabolic benefits, a lifestyle intervention aimed at weight loss in patients with chronic obstructive pulmonary disease (COPD) who are overweight or obese may reduce COPD symptoms, according to results of the INSIGHT COPD trial presented at ATS 2022.
Weight loss intervention may improve COPD symptoms
07 Jun 2022Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
07 Jun 2022Does IBS elevate long-term risk of cancer?
People with irritable bowel syndrome (IBS) are not at increased overall risk of cancer relative to the general population, reveals a study. On the contrary, those with IBS appear to have a lower risk of incident colorectal cancer (CRC) and cancer-specific mortality.
Does IBS elevate long-term risk of cancer?
07 Jun 2022Frail women at risk of complications, repeat procedure after sling surgery
Frailty is associated with a higher relative risk of 30-day complications, 1-year mortality, and repeat procedures for persistent incontinence or obstructed voiding at 1 year after sling surgery in older adults, suggests a recent study.
Frail women at risk of complications, repeat procedure after sling surgery
07 Jun 2022High-dose iberdomide shows promise in phase II SLE trial
In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).
High-dose iberdomide shows promise in phase II SLE trial
07 Jun 2022H. pylori eradication suppresses long-term gastric cancer risk
Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.